• Sleep Cycle shifted its sleep apnea risk detection rollout to pursue EU MDR Class I CE marking for an earlier European launch.
• Certification work starts immediately, targeting EU and UK launch in early 2027.
• FDA clearance plans remain, with additional data collection to be scoped once European commercial evidence is established.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sleep Cycle AB (publ) published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.